Phase I study of vinorelbine plus gemcitabine as third-line chemotherapy for refractory non-small cell lung cancer

  • Authors:
    • Soichiro Ando
    • Makoto Suzuki
    • Tomohiko Iida
    • Takahiro Nakajima
    • Hideki Kimura
  • View Affiliations

  • Published online on: September 1, 2005     https://doi.org/10.3892/or.14.3.689
  • Pages: 689-694
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

For non-small cell lung cancer (NSCLC), which is refractory for both platinum-based chemotherapy and docetaxel, no standard regimen has yet been established. We conducted a phase I study of a combination of vinorelbine and gemcitabine as third-line chemotherapy for refractory NSCLC to determine both the maximum tolerated dose (MTD) and the recommended dose (RD). Twenty patients with NSCLC refractory for both platinum and docetaxel were enrolled, and all patients were eligible for this phase I study. Cohorts of three to seven patients received vinorelbine at doses ranging from 20 to 25 mg/m2, and gemcitabine at doses ranging from 600 to 1000 mg/m2, on days 1 and 8 every 3 weeks. The dose-limiting toxicities were treatment delay, serum γGTP elevation, diarrhea and cerebral infarction, which were resolved without serious sequela, and there was no treatment-related death. The MTD was vinorelbine at 25 mg/m2 and gemcitabine at 1000 mg/m2 and the RD was vinorelbine at 25 mg/m2 and gemcitabine at 800 mg/m2. The median overall survival time was 6.8 months for all 20 patients eligible. As third-line chemotherapy, the combination of vinorelbine and gemcitabine was feasible and promising for NSCLC which is refractory for both platinum and docetaxel.

Related Articles

Journal Cover

September 2005
Volume 14 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ando S, Suzuki M, Iida T, Nakajima T and Kimura H: Phase I study of vinorelbine plus gemcitabine as third-line chemotherapy for refractory non-small cell lung cancer. Oncol Rep 14: 689-694, 2005.
APA
Ando, S., Suzuki, M., Iida, T., Nakajima, T., & Kimura, H. (2005). Phase I study of vinorelbine plus gemcitabine as third-line chemotherapy for refractory non-small cell lung cancer. Oncology Reports, 14, 689-694. https://doi.org/10.3892/or.14.3.689
MLA
Ando, S., Suzuki, M., Iida, T., Nakajima, T., Kimura, H."Phase I study of vinorelbine plus gemcitabine as third-line chemotherapy for refractory non-small cell lung cancer". Oncology Reports 14.3 (2005): 689-694.
Chicago
Ando, S., Suzuki, M., Iida, T., Nakajima, T., Kimura, H."Phase I study of vinorelbine plus gemcitabine as third-line chemotherapy for refractory non-small cell lung cancer". Oncology Reports 14, no. 3 (2005): 689-694. https://doi.org/10.3892/or.14.3.689